SCHEMBL1099313

SCHEMBL1099313

Cc1c(N(CCc2ccccc2)S(=O)(=O)c2ccccc2)sc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 6/20 0.50
NR1I2 O75469 1/20 0.47
HSD11B1 P28845 1/20 0.43
CNR2 P34972 3/20 0.43
BACE1 P56817 2/20 0.38
KEAP1 Q14145 3/20 0.37
NFE2L2 Q16236 3/20 0.37
GAA P10253 1/20 0.36
TSHR P16473 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098991 0.86 TRPM8 (0.51) TRPM8HSD11B1BACE1KEAP1NFE2L2
SCHEMBL1098457 0.85 NR1I2 (0.44) TRPM8NR1I2CNR2BACE1KEAP1
SCHEMBL1098844 0.85 NR1I2 (0.44) TRPM8NR1I2CNR2BACE1KEAP1
SCHEMBL1099202 0.84 TRPM8 (0.48) TRPM8HSD11B1BACE1KEAP1NFE2L2
SCHEMBL1099277 0.84 TRPM8 (0.49) TRPM8NR1I2HSD11B1BACE1KEAP1
SCHEMBL1099646 0.84 TRPM8 (0.49) TRPM8NR1I2HSD11B1KEAP1NFE2L2
SCHEMBL1100499 0.83 TRPM8 (0.53) TRPM8NR1I2HSD11B1
SCHEMBL1098232 0.82 TRPM8 (0.48) TRPM8HSD11B1CNR2KEAP1NFE2L2
SCHEMBL1099774 0.81 TRPM8 (0.52) TRPM8NR1I2HSD11B1
SCHEMBL1099844 0.81 TRPM8 (0.49) TRPM8NR1I2HSD11B1KEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885NR1I2 465/4885HSD11B1 4304/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885NR1I2 465/4885HSD11B1 4304/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885NR1I2 465/4885HSD11B1 4304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.